Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral Fracture

2001 ◽  
Vol 12 (3) ◽  
pp. 207-214 ◽  
Author(s):  
O. Johnell ◽  
A. Oden ◽  
F. Caulin ◽  
J. A. Kanis
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk

scholarly journals Vertebral Fracture Risk With Long-term Corticosteroid Therapy

2000 ◽  
Vol 160 (19) ◽  
pp. 2917 ◽  
Author(s):  
Vasi Naganathan ◽  
Graeme Jones ◽  
Peter Nash ◽  
Geoff Nicholson ◽  
John Eisman ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Corticosteroid Therapy ◽  
Vertebral Fracture Risk

scholarly journals Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

2009 ◽  
Vol 20 (10) ◽  
pp. 1663-1673 ◽  
Author(s):  
P. J. Meunier ◽  
C. Roux ◽  
S. Ortolani ◽  
M. Diaz-Curiel ◽  
J. Compston ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Postmenopausal Women ◽  
Strontium Ranelate ◽  
Vertebral Fracture Risk

scholarly journals Mortality and vertebral fracture risk associated with long-term oral steroid use in patients with chronic obstructive pulmonary disease: A systemic review and meta-analysis

2019 ◽  
Vol 16 ◽  
pp. 147997311983828 ◽  
Author(s):  
Yu-Ping Chang ◽  
Chien-Hao Lai ◽  
Chiung-Yu Lin ◽  
Ya-Chun Chang ◽  
Meng-Chih Lin ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Meta Analysis ◽  
Oral Steroid ◽  
Chronic Obstructive ◽  
Steroid Use ◽  
Obstructive Pulmonary Disease ◽  
Increased Risk ◽  
Vertebral Fracture Risk

Short-term oral steroid use may improve lung function and respiratory symptoms in patients with stable chronic obstructive pulmonary disease (COPD). However, long-term oral steroid (LTOS) use is not recommended owing to its potential adverse effects. Our study aimed to investigate whether chronic use of oral steroids for more than 4 months would increase mortality and vertebral fracture risk in patients with stable COPD. A systemic search of the PubMed database was conducted, and meta-analysis was performed using Review Manager 5.3. Five studies with a total of 1795 patients showed there was an increased risk of mortality in patients using LTOS (relative risk, 1.63; 95% confidence interval (CI), 1.19–2.23; p < 0.0001; I2 = 86%). In addition, four studies with a total of 17,764 patients showed there was an increased risk of vertebral fracture in patients using LTOS (odds ratio, 2.31; 95% CI, 1.52–3.50; p = 0.03; I2 = 65%). Our meta-analysis showed LTOS was associated with increased mortality and vertebral fracture risk in patients with COPD, and this risk may be due to the adverse effects of LTOS and progression COPD.

scholarly journals AB0618 GLUCOCORTICOID INDUCED OSTEOPOROSIS PREVENTION IN THE OUTPATIENT RHEUMATOLOGY CLINIC

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1343.2-1344
Author(s):  
Z. Vaghaiwalla ◽  
G. Kaeley
Keyword(s):  
Vitamin D ◽  
Fracture Risk ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Osteoporosis Prevention ◽  
Osteoporosis Medication ◽  
Rheumatology Clinic ◽  
Dexa Scan ◽  
Audit Cycle

Background:Patients with rheumatic disease are at risk of developing glucocorticoid induced osteoporosis (GIOP) as many are prescribed systemic oral glucocorticoids as an adjunct to their maintenance therapy. Based on the 2017 ACR Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, a good practice recommendation exists that “initial clinical fracture risk assessment should be performed as soon as possible, but at least within six months of the initiation of long term glucocorticoid treatment.1” Long-term glucocorticoid use is defined by duration of 3 months or greater. Fracture risk assessment should include dual energy-ray absorptiometry (DEXA) scan. Patients on greater than or equal to 2.5 mg of prednisone should be treated with an optimal dose of calcium and vitamin D and may benefit from oral bisphosphonate as primary prevention against GIOP if their fracture risk is moderate to high.1Objectives:The aim of this Quality Improvement Project is to assess the current status of provider implementation of GIOP recommendations in the rheumatology clinic. Ultimate goal is to improve osteoporosis prevention in the rheumatology clinic.Methods:We conducted a retrospective chart review of 60 patients in two outpatient rheumatology clinics. Clinic 1 follows patients with lower socioeconomic status and Clinic 2 follows patients with higher socioeconomics. Inclusion criteria were patients on long-term glucocorticoid use, defined as at least 3 months of corticosteroid use of at least 2.5 mg prednisone daily, as well as age less than 65. Females aged 65 or older were omitted to prevent overlap of the United States Preventative Taskforce recommendation for all women ≥ 65 years to be screened for osteoporosis with DEXA scans.2 DEXA scan orders, calcium and vitamin D prescriptions, and osteoporosis medication prescriptions were abstracted. After baseline data obtained, intervention of education of the rheumatology fellows and faculty, and internal medicine residents in the guidelines for GIOP prevention was implemented. In addition, a smartphrase in the electronic medical record was created for provider use when treating patients on chronic corticosteroids. Subsequently, two audit cycles were completed for retrospective chart review.Results:Upon completion of second audit cycle, there was no change in percentage of DEXA scan orders at Clinic 1, however there was a 10% overall improvement in DEXA scan orders in the Clinic 2.In terms of Calcium and Vitamin D prescriptions, there was an overall improvement in both clinics of 19.7% and 13.3% in Clinics 1 and 2 respectfully after the second audit cycle.Additionally, there was a 3.4% increase in osteoporosis medication prescriptions overall subsequent to the second audit cycle in Clinic 1. However in Clinic 2 there was an overall decrease in osteoporosis medication prescriptions of 6.6%.Clinic 1Prior to AuditAudit cycle 1Audit cycle 2Patient percentage without DEXA scan orders30%33.30%30%Patient percentage without Vitamin D/Calcium orders26.40%8.30%6.70%Patient percentage with osteoporosis medication orders23.30%8.30%26.70%Clinic 2Patient percentage without DEXA scan orders50%37.00%40%Patient percentage without Vitamin D/Calcium orders30%26.00%16.70%Patient percentage with osteoporosis medication orders23.30%11.10%16.70%Conclusion:Overall, the results of the intervention were strongest for improvements in Vitamin D and Calcium orders in both clinics. Improvements in DEXA scan orders and osteoporosis medications were present in Clinic 2 and not present in Clinic 1. This reveals continued efforts and education of providers need to be made for improvement in bone health monitoring.References:[1]Buckley, Lenore, et al. “2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.” Arthritis & Rheumatology, vol. 69, no. 8, June 2017, pp. 1521–1537., doi:10.1002/art.40137.[2]Final Recommendation Statement: Osteoporosis to Prevent Fractures: Screening. U.S. Preventive Services Task Force. July 2019.Disclosure of Interests:None declared.

scholarly journals Type 2 Diabetes Mellitus and Vertebral Fracture Risk

2021 ◽  
Author(s):  
Fjorda Koromani ◽  
Samuel Ghatan ◽  
Mandy van Hoek ◽  
M. Carola Zillikens ◽  
Edwin H. G. Oei ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Vertebral Fractures ◽  
Bone Fragility ◽  
Marrow Fat ◽  
Systematic Screening ◽  
Published Evidence ◽  
Vertebral Fracture Risk

Abstract Purpose of Review The purpose of this review is to summarize the recently published evidence concerning vertebral fracture risk in individuals with diabetes mellitus. Recent Findings Vertebral fracture risk is increased in individuals with T2DM. The presence of vertebral fractures in T2DM is associated with increased non-vertebral fracture risk and mortality. TBS could be helpful to estimate vertebral fracture risk in individuals with T2DM. An increased amount of bone marrow fat has been implicated in bone fragility in T2DM. Results from two recent studies show that both teriparatide and denosumab are effective in reducing vertebral fracture risk also in individuals with T2DM. Summary Individuals with T2DM could benefit from systematic screening in the clinic for presence of vertebral fractures.

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

2004 ◽  
Vol 22 (5) ◽  
pp. 462-468 ◽  
Author(s):  
Kazuhiro Kushida ◽  
Masataka Shiraki ◽  
Toshitaka Nakamura ◽  
Hideaki Kishimoto ◽  
Hirotoshi Morii ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Japanese Women ◽  
Follow Up Study ◽  
Vertebral Fracture Risk

Quantitative computed tomography for prediction of vertebral fracture risk

Bone ◽  
1985 ◽  
Vol 6 (1) ◽  
pp. 1-7 ◽  
Author(s):  
C.E. Cann ◽  
H.K. Genant ◽  
F.O. Kolb ◽  
B. Ettinger
Keyword(s):  
Computed Tomography ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Quantitative Computed Tomography ◽  
Vertebral Fracture Risk
Sign in / Sign up

Export Citation Format

Share Document